Article

Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors

Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
PLoS ONE (Impact Factor: 3.53). 04/2011; 6(4):e18164. DOI: 10.1371/journal.pone.0018164
Source: PubMed

ABSTRACT Intervention with antiretroviral treatment (ART) and control of viral replication at the time of HIV-1 seroconversion may curtail cumulative immunological damage. We have therefore hypothesized that ART maintenance over a very prolonged period in HIV-1 seroconverters could induce an immuno-virological status similar to that of HIV-1 long-term non-progressors (LTNPs).
We have investigated a cohort of 20 HIV-1 seroconverters on long-term ART (LTTS) and compared it to one of 15 LTNPs. Residual viral replication and reservoirs in peripheral blood, as measured by cell-associated HIV-1 RNA and DNA, respectively, were demonstrated to be similarly low in both cohorts. These two virologically matched cohorts were then comprehensively analysed by polychromatic flow cytometry for HIV-1-specific CD4(+) and CD8(+) T-cell functional profile in terms of cytokine production and cytotoxic capacity using IFN-γ, IL-2, TNF-α production and perforin expression, respectively. Comparable levels of highly polyfunctional HIV-1-specific CD4(+) and CD8(+) T-cells were found in LTTS and LTNPs, with low perforin expression on HIV-1-specific CD8(+) T-cells, consistent with a polyfunctional/non-cytotoxic profile in a context of low viral burden.
Our results indicate that prolonged ART initiated at the time of HIV-1 seroconversion is associated with immuno-virological features which resemble those of LTNPs, strengthening the recent emphasis on the positive impact of early treatment initiation and paving the way for further interventions to promote virological control after treatment interruption.

0 Followers
 · 
280 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction These guidelines are part of the French Experts’ recommendations for the management of people living with HIV/AIDS, which were made public and submitted to the French health authorities in September 2013. The objective was to provide updated recommendations for antiretroviral treatment (ART) of HIV-positive adults. Guidelines included the following topics: when to start, what to start, specific situations for the choice of the first session of antiretroviral therapy, optimization of antiretroviral therapy after virologic suppression, and management of virologic failure. Methods Ten members of the French HIV 2013 expert group were responsible for guidelines on ART. They systematically reviewed the most recent literature. The chairman of the subgroup was responsible for drafting the guidelines, which were subsequently discussed within, and finalized by the whole expert group to obtain a consensus. Recommendations were graded for strength and level of evidence using predefined criteria. Economic considerations were part of the decision-making process for selecting preferred first-line options. Potential conflicts of interest were actively managed throughout the whole process. Results ART should be initiated in any HIV-positive person, whatever his/her CD4 T-cell count, even when >500/mm3. The level of evidence of the individual benefit of ART in terms of mortality or progression to AIDS increases with decreasing CD4 cell count. Preferred initial regimens include two nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine) plus a non-nucleoside reverse transcriptase inhibitor (efavirenz or rilpivirine), or a ritonavir-boosted protease inhibitor (atazanavir or darunavir). Raltegravir, lopinavir/r, and nevirapine are recommended as alternative third agents, with specific indications and restrictions. Specific situations such as HIV infection in women, primary HIV infection, severe immune suppression with or without identified opportunistic infection, and person who injects drugs are addressed. Options for optimization of ART once virologic suppression is achieved are discussed. Evaluation and management of virologic failure are described, the aim of any intervention in such situation being to reduce plasma viral load to <50 copies/ml. Conclusion These guidelines recommend that any HIV-positive individual should be treated with ART. This recommendation was issued both for the patient’s own sake and for promoting treatment as prevention.
    Journal of the International AIDS Society 06/2014; 17(1):19034. DOI:10.7448/IAS.17.1.19034 · 4.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigate a control systems analysis on HIV infection dynamics with regard to enhancement of the immune response. The HIV dynamic model is modified to include the pharmacokinetics and pharmacodynamics of antiretroviral HIV drugs, and the intake of drug is considered as impulsive control input. As it is administrated at discrete time instants, we assume that this yields an impulsive control problem for a nonlinear continuous-time system. Based on this new model, we study clinical experiments about antirretoviral treatments via numerical simulation and analyse the experimental results. It is noted that this modeling approach can help to provide a theoretical explanation of the clinical results. The analysis result in the paper could imply that the protocol of the experiment might enhance the immune response against HIV.
    Biomedical Signal Processing and Control 09/2014; 13:123–131. DOI:10.1016/j.bspc.2014.03.008 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV replication control is important to reduce AIDS progression. We determined frequency and activation status of immune cells in spontaneous HIV controllers vs. individuals with HAART controlled viral load. HIV controllers exhibited significantly higher frequency of CD4+ T-cells and myeloid dendritic cells compared to HAART controlled viral load. Additionally, HIV controllers have a significantly lower percentage of cells expressing activation markers on CD4 and CD8 T-cells, myeloid dendritic cells and natural killer cells.These findings suggest that during HIV infection, conservation of a normal frequency and physiological range of immune activation is associated with spontaneous, but not HAART-induced control of viral replication.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 04/2014; DOI:10.1097/QAI.0000000000000162 · 4.39 Impact Factor

Full-text (2 Sources)

Download
54 Downloads
Available from
Jun 3, 2014